Record Orders Can't Bridge the Margin Gap

On the surface, Q2 looks robust: revenue of ₹1,064.6 crore grew 18% year-on-year, and order intake hit a record ₹1,198 crore. Both supported the company's growth narrative. But underneath, margin compression told a different story. Reported EBITDA fell 210 basis points year-on-year to 10.3%, and net profit declined 10.8% despite the top-line surge — a failure of margin leverage that investors did not forgive. The stock fell 9.5% on day 1 of the result announcement.

The culprit is European losses. In H1 FY27, loss-making entities (primarily Germany, Switzerland, and UK-transition costs) posted a combined EBITDA loss of approximately ₹43 crore. Excluding these losses, the core business would have delivered a 15.9% EBITDA margin in Q2 — exactly in line with management's claimed range of 14%–15%. What is being masked is material. The company is in the midst of an aggressive restructuring: UK facility closed, German plants being rationalized, and production being shifted to Poland. These moves are ongoing; the benefit is promised for H2 FY27 and FY28. For now, the costs are real and large. Reported margins will lag core until that restructuring pays off.

In Q1, management reaffirmed a 15% EBITDA margin aspiration and guided for a path to that target. On this call, that aspiration was downgraded to a 10%–11% expected margin for FY27, a frank acknowledgment that European restructuring costs and losses would drag reported numbers. This is credible: the company stopped hiding the drag and explicitly called out ₹43 crore in H1 EBITDA losses from loss-making entities. Management also tightened the narrative around restructuring timing — most German costs are now behind them, but full benefits are phased into H2 and FY28. On a positive note, management was transparent about the margin split (core 14%–15% vs. reported 10%), a shift from Q1's opacity. Debt reduction is on track: net debt fell ₹116 crore in H1, and refinancing initiatives are progressing. Tax rate is normalizing toward the 30% target.

Against the margin disappointment sits genuine strength in order momentum. Q2 order intake reached ₹1,198 crore, up 36% year-on-year, and the order backlog now stands at ₹2,446 crore (up 14% YoY and 2.3x quarterly revenue). Management highlighted three secular tailwinds: pharma and CDMO capacity expansion (orders ₹150 crore in the last 6 months alone, driven by peptide equipment), defence and NATO investments (Bulgaria order worth $30 million, NATO-validated acid concentration technology), and thermal/nuclear power (HET segment up 38% YoY). Critically, 44% of H1 orders now come from non-traditional sectors, up from historical lows. The risk: this backlog came at softer market pricing in prior periods. Management claims the current order environment is more profitable, and pricing is recovering in India. That claim will be tested in H2 conversion.

Price action: The market's initial verdict was sharp. The stock fell 9.5% on day 1 of the result announcement and extended to a 13.3% decline by day 3, signaling the margin miss and guidance cut were not priced in. By day 5, the move had moderated to 6.9%, suggesting stabilization or covering. Over the following days, the stock partially recovered, closing at ₹1,239.3 as of publication. This pattern — initial shock followed by gradual recovery — is typical of a story where fundamentals were disappointing but the bull narrative (order backlog, restructuring) retained some credibility.

Valuation and drawdown context: The stock is down 46.2% from its all-time high of ₹2,304.6, but up 68.6% from its 52-week low. At ₹1,239.3, it trades above the 20-day moving average (₹1,234.31) and well above the 200-day average (₹991.82), but below the 50-day average (₹1,308.93). RSI is 49.1 (neutral). This positioning suggests stabilization after the shock, but no upside conviction yet. The question: is the 46% drawdown from ATH a margin-of-safety entry the bull case claims, or the beginning of a longer re-rating downward?

Ownership flows: Foreign institutional investors trimmed their stake from 17.15% in Q4 FY26 to 14.39% in Q1 FY27 — a 2.76 percentage point outflow. Domestic institutional investors added (from 17.59% to 18.42%), stepping in to buy the dip. This classic divergence — FII exits on execution risk, DII adds on value — is telling. The FII outflow signals international investors are not yet convinced the margin recovery will materialize on schedule. A reversal of this trend would be bullish.

Bulk deals: In early September 2026, Persistence Capital Fund I (a VC/PE investor) bought 2.4 million shares at ₹1,236.11 per share — at a price very close to current levels. This meaningful addition by a sophisticated investor suggests some conviction the restructuring story will work. No promoter or insider selling near highs has been flagged.